This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. New Engl J Med. 2018;378:1107–20.
Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34:3758–65.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood. 2011;117:1817–21.
Gentile M, Cutrona G, Molica S, Ilariucci F, Mauro FR, Di Renzo N, et al. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Eur J Haematol. 2016;96:36–45.
Muntanola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Gine E, et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1576–80.
Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89:2516–22.
Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–16.
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.
Herndon TM, Chen S-S, Saba NS, Valdez J, Emson C, Gatmaitan M, et al. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 2017;31:1340–7.
Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Investig. 2005;115:755–64.
Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia. 2013;27:1949.
Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131:955–62.
EMA (European Medicines Agency). Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man - condition specific guidance. EMA; 2016. https://www.emaeuropaeu/en/appendix-4-guideline-evaluation-anticancer-medicinal-products-man-condition-specific-guidance.
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37:269–77.
Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D, et al. Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nat Commun. 2017;8:14756.
Acknowledgements
We wish to thank the patients and their treating physicians who participated in the trials. The data have not been previously published or submitted for publication. Parts of the data have been presented as a poster at the 60th ASH annual meeting 2018 in San Diego. The CLL2M and CLL10 trials were conducted as investigator-initiated trials by the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). They were supported by research grants from Roche Pharma AG, and Mundipharma and a grant from the German Federal Ministry of Education. The CLL8 study was conducted as an investigator-initiated trial by the GCLLSG from 2003 to 2004 and afterwards sponsored by F. Hoffmann-La Roche.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
MF, EL, and PD declare that they have no competing interests. JB reports personal fees (travel support) from Roche. AMF reports personal fees (advisory board) from Janssen Pharmaceutical during the conduct of the study. MD reports personal fees from Acerta, Bayer, Gilead, Novartis, Sandoz, grants and personal fees from Celgene, Janssen, Roche, and grants from Mundipharma outside the submitted work. DGH reports personal fees from Janssen, grants and personal fees from Roche, personal fees from Abbvie, personal fees from Gilead, personal fees from Novartis, grants from Pfizer, personal fees from Morphosys, and grants and personal fees from Celgene. MR reports grants from Roche during the conduct of the study, and personal fees from Roche outside the submitted work. MK reports personal fees from Roche and AbbVie. SS reports grants, personal fees, and nonfinancial support from AbbVie, grants, personal fees, and nonfinancial support from Amgen, grants, personal fees, and nonfinancial support from AstraZeneca, grants, personal fees, and nonfinancial support from Celgene, grants, personal fees, and nonfinancial support from Gilead, grants, personal fees, and nonfinancial support from GSK, grants, personal fees, and nonfinancial support from Hoffmann-La Roche, grants, personal fees, and nonfinancial support from Janssen, grants, personal fees, and nonfinancial support from Novartis, grants, personal fees, and nonfinancial support from Pharmacyclics, and grants, personal fees, and nonfinancial support from Sunesis outside the submitted work. HD reports personal fees from Agios, AbbVie, Amgen, Astellas, Astex, Celator, Celgene, Janssen, Jazz, Novartis, Seattle Genetics, and Sunesis and research funding from AROG, Bristol Myers Squibb, Celgene, Novartis, Pfizer, and Sunesis. CMW reports grants and personal fees from Hoffmann-La Roche, grants and personal fees from Mundipharma during the conduct of the study, grants and personal fees from Hoffmann-La Roche, grants and personal fees from Mundipharma, grants and personal fees from Janssen-Cilag, grants and personal fees from AbbVie, grants and personal fees from Gilead, grants and personal fees from Novartis, grants and personal fees from Celgene, and grants and personal fees from MorphoSys outside the submitted work. VG reports personal fees from Roche, personal fees from Janssen, personal fees from Gilead, personal fees from AbbVie, outside the submitted work. KF reports personal fees (travel support) from Roche. SB reports personal fees from Roche, AbbVie, Janssen, research funding from Roche, AbbVie, Celgene, Genentech, and appeared on an advisory board for Roche. MH reports research grants from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, and Abbvie. Speakers bureau and Advisory Board for Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, Boehringer. BE reports research grants from Abbvie, Gilead, Janssen, Roche, and Beigene and personal fees, advisory boards from the same companies and Celgene and Novartis in addition.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fürstenau, M., Bahlo, J., Fink, A.M. et al. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia 34, 924–928 (2020). https://doi.org/10.1038/s41375-019-0597-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0597-3
This article is cited by
-
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Blood Cancer Journal (2021)